Fig. 1 · Structure

Documents & Downloads

Indocyanine green

Cat. No. A10472 CAS 3599-32-4
Indocyanine green is a cyanine dye used in medical diagnostics. It is used for determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography.

In Stock

Publications for Indocyanine green

10 publications citing this product

  1. Alap Ali Zahid, .et al. , Advanced Functional Materials, 2026, 36:e24571
  2. Mishal Pokharel, .et al. , Pharmaceutics, 2025, Aug 1;17(8):1007 PMID: 40871028
  3. Hamoud Alotaibi, .et al. , Eur J Pharm Biopharm, 2025, Aug:213:114747 PMID: 40379109
  4. Siyang Wu, .et al. , Eur J Pharm Sci, 2025, May 1:208:107049 PMID: 39988263
  5. Hamoud Alotaibi, .et al. , Eur J Pharm Sci, 2025, Apr 1:207:107034 PMID: 39922238
  6. Wafa T Al-Jamal, .et al. , Int J Pharm, 2025, Jan 5:668:124963 PMID: 39557180
  7. Shruti Vig, .et al. , Cancer Drug Resist, 2024, Sep 21:7:35 PMID: 39403604
  8. Antti I Nykanen, .et al. , J Thorac Cardiovasc Surg, 2022, Mar 11;S0022-5223(22)00248-3 PMID: 35382935
  9. Lei Li, .et al. , ACS Nano, 2021, Jan 19 PMID: 33464827
  10. Adrian Rosenberg, .et al. , Mol Imaging, 2020, Jan-Dec; 19: 1536012120934965 PMID: 32609570

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Indocyanine green (ICG) fluorescence depends on its formulation and local environment. In a cell-free DSPC:DSPEmPEG2000 liposome system, fluorescence yield peaked at a lipid:ICG molar ratio of 250:1 among the ratios tested. This formulation also preserved fluorescence during dark storage at 4 °C more effectively than free ICG in buffer. These results describe prepared liposomes and assay-specific fluorescence stability. [1]

Cellular ICG uptake can involve endocytic processes. In HT-1080 cells, Pitstop 2 pretreatment reduced ICG fluorescence in a microscopy assay, while a related inactive control did not. Inhibition was incomplete, and Pitstop 2 has only partial pathway selectivity; the result supports a Pitstop-sensitive uptake component without establishing an exclusive clathrin-mediated mechanism. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Indocyanine green Research Summary

This section summarizes 4 in vitro studies and 2 in vivo studies of Indocyanine green from 4 published references. In vitro models include cell-free DSPC:DSPEmPEG2000 liposomes versus soluble ICG; free ICG in buffer versus lipid-incorporated ICG at lipid:ICG 250:1.

Indocyanine green In Vitro Studies

ICG uptake was not specific to tumor cells in a microscopy comparison of SCC026 carcinoma and HaCaT non-tumor skin cells. At 0.6 μg/ml, both cell lines showed living-cell uptake after 2.5 h, while dead cells showed uptake after 1 min. The study provides a qualitative limit on interpreting ICG fluorescence as selective tumor-cell labeling. [3]

Lipid-ratio dependence of ICG fluorescence

Biochemical assay · Cell-free DSPC:DSPEmPEG2000 (9:1 molar ratio) liposomes versus soluble ICG [1]

Fluorescence yield varied with lipid:ICG ratio. The 250:1 formulation gave the highest fluorescence per unit ICG among the eight tested ratios; increasing the ratio further did not continue to improve yield.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Highest fluorescence yield among tested formulationslipid:ICG molar ratio 250:1[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.01–2.0 μM ICG for fluorescence measurements; eight lipid:ICG ratios spanning 100:1–500:1
Method
Plate-reader fluorescence; excitation 769 ± 41 nm, emission 832 ± 37 nm
Vehicle
0.9% NaCl, 20 mM NaHCO3 buffer, pH 7
Co-treatment
DSPC:DSPEmPEG2000 9:1 liposomal formulation; soluble ICG comparator
Reported limits
Measurement incubation duration not specified for this formulation comparison.
Methods and source locations

Compound reported in the paper: Indocyanine green; Compound label in the paper: Sigma-Aldrich ICG, sodium form (C43H47N2NaO6S2), free and lipid-incorporated

Supports formulation-dependent optical behavior; the catalog material is not a preformed liposome.

Experimental Procedures: Chemicals, Liposome Preparation, Fluorescence; Results: Incorporation of ICG into Lipid Membranes To Stabilize and Maximize ICG Fluorescence; Figure 3B–C

Highest fluorescence yield among tested formulations: Fluorescence intensity per μM ICG (slope); Figure 3B points mean ± SD, eight replicates; Figure 3C points mean ± SD, six replicates. — Figure 3B–C and caption; corresponding Results subsection

Storage-dependent loss of free and liposomal ICG fluorescence

Biochemical assay · Free ICG in buffer versus lipid-incorporated ICG at lipid:ICG 250:1 [1]

During dark storage at 4 °C, free ICG lost fluorescence much faster than the specific liposomal formulation. These are fluorescence-decay endpoints, not chemical-purity or catalog shelf-life measurements.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fluorescence retained at 8 months, relative to initial signal% initial fluorescence Liposomal ICG: 78.2 ± 2.8%; free ICG: 0.3 ± 0.2%[1]
Fitted half-life of fluorescence during dark storage at 4 °Ct1/2 (days) Liposomal ICG: 394 (95% CI 360–434); free ICG: 1.19 (95% CI 1.14–1.25)[1]

Literature-Reported Treatment Conditions

Exposure duration
Up to 313 days for liposomal ICG; free-ICG fit used five time points over 239 days; Table 1 reports 8-month fluorescence.
Method
Fluorescence measured during storage; exponential decay model
Vehicle
0.9% NaCl, 20 mM NaHCO3 buffer, pH 7
Co-treatment
Liposomal arm: DSPC:DSPEmPEG2000 9:1, lipid:ICG 250:1; free ICG comparator
Reported limits
Storage-sample ICG concentration was not separately restated in the storage paragraph; 2.0 μM is explicitly given for the distinct light-exposure test and is not transferred here. No chemical degradation-product analysis supports these fluorescence endpoints.
Methods and source locations

Compound reported in the paper: Indocyanine green; Compound label in the paper: Sigma-Aldrich ICG sodium, free versus lipid-incorporated

Condition-specific fluorescence stability only; does not establish dry-powder shelf life.

Experimental Procedures: Light Exposure and Storage Stability; Results: Effects of Lipid Incorporation on Enhancing ICG Stability for Light Exposure and Storage; Figure 5; Table 1

Fluorescence retained at 8 months, relative to initial signal: Table 1: mean ± SD, N = 2 samples each at 8 months. Figure 5 time-course points have three to eight replicates. — Table 1, column % ICG fluorescence (8 months), footnotes a–b; Figure 5

Fitted half-life of fluorescence during dark storage at 4 °C: Exponential decay model. Liposomal fit: N = 10 time points over 313 days; free fit: N = 5 time points over 239 days; these N values are not animal/sample counts. — Table 1, t1/2 column and footnotes c–d; Figure 5

Qualitative ICG uptake in carcinoma and non-tumor cells

Cell-based study · Human squamous cell carcinoma SCC026 and immortalized non-cancer skin HaCaT cells [3]

Both cell lines showed uptake into living cells after 2.5 h; dead cells took up ICG earlier. The authors found no distinct tumor-cell-specific uptake in this model. Images used automatically chosen exposure times and do not establish equal uptake magnitudes.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Timing of detectable cellular ICG signalqualitative microscopy Dead-cell uptake observed after 1 min; no notable living-cell uptake during the first 90 min; living-cell internalization observed at 2.5 h in both cell lines.[3]

Literature-Reported Treatment Conditions

Treatment concentration
0.6 μg/ml ICG
Exposure duration
1, 45 and 90 min, 2.5 and 24.0 h incubation
Method
ICG fluorescence microscopy with calcein AM/ethidium homodimer-1 live/dead staining; washes before imaging
Vehicle
Fresh cell growth medium containing ICG; SCC026: MEM with 20% fetal bovine serum and 2 mM L-glutamine; HaCaT: DMEM with 10% fetal bovine serum and 2 mM L-glutamine
Co-treatment
No therapeutic combination; live/dead stains used as markers. Matched cells without ICG underwent the same incubation/staining.
Reported limits
Biological replicate count and quantitative uptake statistics not stated in selected cell-culture methods/results. No-ICG control/cell-survival results are described as data not shown.
Methods and source locations

Compound reported in the paper: Indocyanine green; Compound label in the paper: ICG (Verdye, Diagnostic Green GmbH)

Qualitative uptake and selectivity limitation for the named formulation and models.

Materials and methods: Fluorescence microscopy; Results: ICG imaging of cell cultures; Figure 1A–C and caption; Discussion

Timing of detectable cellular ICG signal: Figure 1A–B; live/dead staining. Earlier time-course absence is reported in Results as data not shown. No signal intensities estimated from images. — Results: ICG imaging of cell cultures; Figure 1A–B and caption

Partial inhibition of cellular ICG uptake by Pitstop 2

Cell-based study · HT-1080 human sarcoma cells [2]

Pitstop 2 pretreatment reduced intracellular ICG fluorescence in the microscopy assay relative to ICG alone and the Pitstop 2 negative-control compound. Uptake was not fully suppressed to the no-ICG baseline. The authors note that Pitstop 2 has only partial endocytosis-pathway selectivity, limiting attribution to clathrin alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mean ICG fluorescence intensity per cell after inhibitor pretreatmentreported paired t-test P value 30 μM Pitstop 2 versus ICG-only control: P < 0.001; inhibition remained incomplete.[2]

Literature-Reported Treatment Conditions

Treatment concentration
ICG 25 μM; Pitstop 2 5–30 μM or negative-control compound 30 μM
Exposure duration
Inhibitor pretreatment for 15 min, followed by ICG for 30 min in continued inhibitor presence
Method
Fluorescence microscopy, main Figure 4; ICG excitation 670–745 nm and emission 768–850 nm; DAPI nuclear counterstain
Vehicle
Serum-free DMEM/F-12 with 15 mM HEPES; inhibitor solutions described as containing 0.1% DMSO before ICG addition
Co-treatment
Pitstop 2 or structurally related inactive negative-control compound; ICG-only and no-ICG controls shown in Figure 4.
Reported limits
Final DMSO fraction after ICG addition is not separately specified. Biological replicate count for Figure 4 is not stated in the read main-text methods/caption. Supplementary details not retrieved due access challenge.
Methods and source locations

Compound reported in the paper: Indocyanine green; Compound label in the paper: Clinical-grade ICG (Verdye, Diagnostic Green), lyophilized powder

Evidence for a Pitstop-sensitive component of cellular uptake under the stated conditions; insufficient to establish exclusive clathrin-mediated uptake or tumor selectivity.

Materials and methods: Fluorescent agents, Cell culture, Inhibition of clathrin-mediated endocytosis, Fluorescence microscopy, Image quantification; Results: Inhibition of clathrin-mediated endocytosis reduces ICG cellular uptake; Figure 4A–B and caption; Discussion

Mean ICG fluorescence intensity per cell after inhibitor pretreatment: 40× microscopy images quantified per cell using DIC-guided polygonal outlines in ZEN Blue v3.3. Figure 4B values shown with 95% CI. Exact effect sizes and replicate counts not inferred. — Materials and methods: Fluorescent agents, Cell culture, Inhibition of clathrin-mediated endocytosis, Fluorescence microscopy, Image quantification; Results: Inhibition of clathrin-mediated endocytosis reduces ICG cellular uptake; Figure 4A–B and caption; Discussion

Indocyanine green In Vivo Studies

In A431 tumor-bearing mice, free ICG was used to image acute changes after Pan-IR700 near-infrared photoimmunotherapy. Intravenous ICG at 0.3 or 1 mg kg−1 produced treated-tumor contrast over 60 min; 0.1 mg kg−1 did not reliably distinguish tumor from background. A paired bilateral-tumor experiment at 0.3 mg kg−1 also favored the illuminated tumor over its shielded counterpart. These findings concern imaging after a separate therapeutic treatment and are limited to the tested subcutaneous xenograft model. [4]

ICG imaging after photoimmunotherapy: unilateral tumors

Animal study · Female athymic nude mice, 6–8 weeks old, with unilateral subcutaneous A431 flank tumors [4]

After Pan-IR700 NIR-PIT, ICG retention in treated tumors was detectable at 0.3 and 1 mg kg−1, while laser-only controls showed no tumor uptake above background. The 0.1 mg kg−1 dose did not reliably distinguish tumor from background.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Treated tumor-to-background fluorescence at 60 min compared with 1 mg kg−1 laser-only controlreported P value 0.3 mg kg−1: P < .001; 1 mg kg−1: P < .0001[4]
Discrimination of tumor from background at low ICG dosequalitative limiting result 0.1 mg kg−1 did not reliably produce different tumor versus background uptake.[4]

Conditions shared by the study groups

Route
Intravenous, tail vein
Frequency
Single ICG injection
Treatment course
ICG immediately after illumination; follow-up through 60 min
Vehicle
H2O:PBS 1:4
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Pan-IR700 plus light, then ICG
ICG 1, 0.3 or 0.1 mg kg−1
Laser-only mice received no Pan-IR700; n = 3 per control group.n = 5 per treatment group. Clear retention at 0.3 and 1 mg kg−1; unreliable discrimination at 0.1 mg kg−1.[4]
Laser-only control, then ICG
ICG 1, 0.3 or 0.1 mg kg−1
No Pan-IR700; same ICG dose groups and illumination.n = 3 per control group. Tumor fluorescence not observably higher than background (P > .05 in Results). Formal comparisons used the 1 mg kg−1 control group.[4]
Pan-IR700 plus light, then ICG
Model: Female athymic nude mice, 6–8 weeks old, with unilateral subcutaneous A431 flank tumors
Reported limits: ICG SKU/lot and exact excluded-animal count not reported.
Laser-only control, then ICG
Model: Female athymic nude mice, 6–8 weeks old, with unilateral subcutaneous A431 flank tumors
Reported limits: ICG SKU/lot and exact excluded-animal count not reported.
Methods and source locations

Compound reported in the paper: Indocyanine green; Compound label in the paper: Free ICG (Adooq Biosciences LLC)

Research imaging after a separate Pan-IR700 treatment in a subcutaneous mouse xenograft model.

In Vivo Murine NIR-PIT Experiments; Statistical and Image Analysis; Results: Real-Time In Vivo Fluorescence After NIR-PIT: Unilateral Tumor Models; Figure 1 and caption; Discussion

Treated tumor-to-background fluorescence at 60 min compared with 1 mg kg−1 laser-only control: Figure 1 means ± SEM; n = 5 per treatment group, n = 3 per control group; 10-second fluorescence averages; unpaired t-test with Welch correction per Methods. Background: contralateral flank. — Figure 1 and caption; Statistical and Image Analysis; unilateral Results

Discrimination of tumor from background at low ICG dose: Author interpretation in Discussion, consistent with viewed Figure 1. No exact ratio inferred from curve. — Discussion, low-dose limitation; Figure 1

Pan-IR700 plus light, then ICG · In Vivo Murine NIR-PIT Experiments; Statistical and Image Analysis; Results: Real-Time In Vivo Fluorescence After NIR-PIT: Unilateral Tumor Models; Figure 1 and caption; Discussion

Laser-only control, then ICG · In Vivo Murine NIR-PIT Experiments; Statistical and Image Analysis; Results: Real-Time In Vivo Fluorescence After NIR-PIT: Unilateral Tumor Models; Figure 1 and caption; Discussion

ICG imaging after photoimmunotherapy: paired tumors

Animal study · Female athymic nude mice bearing bilateral subcutaneous A431 flank tumors [4]

Within each mouse, the illuminated tumor retained more ICG fluorescence than the shielded tumor after NIR-PIT. This paired design supports treatment-associated imaging contrast, not tumor targeting by ICG alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Treated-to-shielded tumor fluorescence ratio over 60 minqualitative paired comparison Ratio increased after ICG injection; ex vivo fluorescence at 60 min favored the treated tumor.[4]

Conditions shared by the study groups

Route
Intravenous, tail vein
Frequency
Single ICG injection
Treatment course
ICG immediately after illumination; follow-up through 60 min
Vehicle
H2O:PBS 1:4
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Paired illuminated and shielded tumors
ICG 0.3 mg kg−1
Right tumor shielded from laser; both tumors in the same Pan-IR700-treated mouse.n = 3 mice; preferential retention in illuminated left tumor over shielded right tumor.[4]
Paired illuminated and shielded tumors
Model: Female athymic nude mice bearing bilateral subcutaneous A431 flank tumors
Reported limits: ICG SKU/lot and exact excluded-animal count not reported.
Methods and source locations

Compound reported in the paper: Indocyanine green; Compound label in the paper: Free ICG (Adooq Biosciences LLC)

Research imaging after a separate Pan-IR700 treatment in a subcutaneous mouse xenograft model.

In Vivo Murine NIR-PIT Experiments; Results: In Vivo Fluorescence Videography After NIR-PIT: Bilateral Tumor Models; Figure 3A–B and caption

Treated-to-shielded tumor fluorescence ratio over 60 min: n = 3; Figure 3A means ± SEM and 10-second averages. Figure 3B ex vivo comparison viewed; no exact ratio digitized. — Figure 3A–B and caption; bilateral Results

Paired illuminated and shielded tumors · In Vivo Murine NIR-PIT Experiments; Results: In Vivo Fluorescence Videography After NIR-PIT: Bilateral Tumor Models; Figure 3A–B and caption

Specifications

Manufacturer Adooq Bioscience
CAS Number 3599-32-4
Formula C43H47N2NaO6S2
Molecular Weight 775
Synonyms Cardiogreen; IR-125
SMILES
CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CCCCS(=O)(=O)[O-])/C=C/C=C/C=C/C=C/4\C(C5=C(N4CCCCS(=O)(=O)[O-])C=CC6=CC=CC=C65)(C)C)C.[Na+]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 138 mg/mL (178.07 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Indocyanine green Research References

  1. [1] Kraft JC, Ho RJ. Interactions of indocyanine green and lipid in enhancing near-infrared fluorescence properties: the basis for near-infrared imaging in vivo Biochemistry (2014). PMID: 24512123 DOI: 10.1021/bi500021j Source material
  2. [2] Chan CD, Brookes MJ, Pringle TA, et al. Investigating the mechanisms of indocyanine green tumour uptake in sarcoma cell lines and ex vivo human tissue The Journal of pathology (2025). PMID: 40928629 DOI: 10.1002/path.6473 Source material
  3. [3] Nguyen HN, Pertzborn D, Ziadat R, et al. Indocyanine green uptake by human tumor and non‑tumor cell lines and tissue Biomedical reports (2024). PMID: 39114300 DOI: 10.3892/br.2024.1824 Source material
  4. [4] Rosenberg A, Fujimura D, Okada R, et al. Real-Time Fluorescence Imaging Using Indocyanine Green to Assess Therapeutic Effects of Near-Infrared Photoimmunotherapy in Tumor Model Mice Molecular imaging (2020). PMID: 32609570 DOI: 10.1177/1536012120934965 Source material

Publications

10 publications citing this product

  1. Alap Ali Zahid, .et al. , Advanced Functional Materials, 2026, 36:e24571
  2. Mishal Pokharel, .et al. , Pharmaceutics, 2025, Aug 1;17(8):1007 PMID: 40871028
  3. Hamoud Alotaibi, .et al. , Eur J Pharm Biopharm, 2025, Aug:213:114747 PMID: 40379109
  4. Siyang Wu, .et al. , Eur J Pharm Sci, 2025, May 1:208:107049 PMID: 39988263
  5. Hamoud Alotaibi, .et al. , Eur J Pharm Sci, 2025, Apr 1:207:107034 PMID: 39922238
  6. Wafa T Al-Jamal, .et al. , Int J Pharm, 2025, Jan 5:668:124963 PMID: 39557180
  7. Shruti Vig, .et al. , Cancer Drug Resist, 2024, Sep 21:7:35 PMID: 39403604
  8. Antti I Nykanen, .et al. , J Thorac Cardiovasc Surg, 2022, Mar 11;S0022-5223(22)00248-3 PMID: 35382935
  9. Lei Li, .et al. , ACS Nano, 2021, Jan 19 PMID: 33464827
  10. Adrian Rosenberg, .et al. , Mol Imaging, 2020, Jan-Dec; 19: 1536012120934965 PMID: 32609570

Added to your cart

View Cart Checkout
Loading...